Quantcast

Latest acute intermittent porphyria Stories

2011-02-16 05:11:00

In the news release, "Amsterdam Molecular Therapeutics Reports Full Year Results 2010" issued on 16 Feb 201106:00 GMT, by Amsterdam Molecular Therapeutics B.V AEX:AMT over PR Newswire, we are advised by a representative of the company that the full year figures should have been included in the dissemination. Complete, corrected release follows AMSTERDAM, February 16, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene...

2011-02-15 23:59:00

AMSTERDAM, February 16, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010. Key Highlights - Glybera(R) Marketing Authorisation Application remains on track with European Medicines Agency (EMA); - Responses to Day 120 questions submitted in November 2010; - Day 180 list of Outstanding Issues now received; - Raised EUR14.3...

2011-02-03 08:59:00

MADRID, February 3, 2011 /PRNewswire/ -- Digna Biotech and the Centro de Investigacion Medica Aplicada (CIMA) de la Universidad de Navarra announced today that the European Union (EU) has finalized a EUR 3.3 million grant to AIPGENE consortium. Digna Biotech and CIMA will receive, as members of the consortium, EUR 0.5 and EUR 0.8 million respectively for the clinical development of a gene therapy product for Acute Intermittent Porphyria (AIP). The AIPGENE consortium is led by CIMA...

2011-01-30 23:59:00

AMSTERDAM, The Netherlands, January 31, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Union (EU) has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria (AIP). AIP is a severe and progressive disease caused by the inability of the body to produce the heme protein,...

2010-02-24 00:51:00

AMSTERDAM, February 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the year to December 31, 2009. Highlights - Glybera(R) Marketing Authorisation Application submitted to European Medicines Agency (EMA, formerly known as EMEA); - EMA commenced formal review of Glybera(R) dossier on January 20, 2010; - EMA grants orphan drug designation for AMT's...

2009-12-02 00:00:00

AMSTERDAM, December 2 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a number of management changes. Piers Morgan (age 43) has been appointed Chief Financial Officer, effective December 1, 2009. Hans Preusting, PhD (age 47), Director Process Development & Manufacturing, will take up the responsibility for Operations and Project Management, also effective December 1. These changes reflect the...

2009-05-28 00:00:00

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP). Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related